Eli Lilly and Company (NYSE:LLY) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 800 shares of the company’s stock after selling 26 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $466,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $27,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $35,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $36,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 6.0 %

LLY stock opened at $781.56 on Wednesday. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The firm has a market cap of $742.61 billion, a PE ratio of 134.75, a P/E/G ratio of 1.61 and a beta of 0.34. The firm has a 50 day simple moving average of $761.41 and a 200 day simple moving average of $669.21. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the business earned $1.62 earnings per share. The business’s quarterly revenue was up 26.0% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Truist Financial upped their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $733.65.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.